Q2 2018 13F Holders as of 30 Jun 2018
-
Type / Class
-
Debt / NOTE 3.250%11/0
-
Number of holders
-
20
-
Total 13F principal, excl. options
-
223,708,000
-
Principal change
-
+862,000
-
Total reported value, excl. options
-
$221,274,000
-
Value change
-
+$773,286
-
Number of buys
-
6
-
Number of sells
-
8
-
Price
-
$0.9905
Institutional Holders of THERAVANCE BIOPHARMA INC - NOTE 3.250%11/0 as of Q2 2018
As of 30 Jun 2018 THERAVANCE BIOPHARMA INC - NOTE 3.250%11/0 had 22 institutional bondholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions held a total of $223,708,000 principal (par value or face value) of the bond of the company.
Largest 10 bondholders included Linden Advisors LP, BAUPOST GROUP LLC/MA, CITADEL ADVISORS LLC, WOLVERINE ASSET MANAGEMENT LLC, ZAZOVE ASSOCIATES LLC, Castle Creek Arbitrage, LLC, LAZARD ASSET MANAGEMENT LLC, MORGAN STANLEY, FMR LLC, and Context Capital Management, LLC.
This table shows 22 bond principal holders of the security as of 30 Jun 2018.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Principal |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.